Skip to main content

Table 1 Spontaneous regression (SR) of small cell lung cancer: a review of literature

From: Pathologically confirmed spontaneous regression of small cell lung cancer after computed tomography-guided percutaneous transthoracic needle biopsy followed by surgery

 

First author

Years

Age

Sex

Biopsy before SR

Shrinkage percentage (duration)

Treatment modality after SR

Stage

OS (months)

1

Shibata7

2021

83

F

TBNA

100% (7 years)

BSC

Unknown

108

2

Song8

2021

80

M

Bronchoscopic biopsy

Unknown (52 months)

BSC

Unknown (LD)

53

3

Ugajin9

2019

82

M

TBLB

100% (18 months)

BSC

c-IIIB

18

4

Inui10

2015

69

F

TBLB

37.5% (unknown)

Surgery (segmentectomy)

Adjuvant chemotherapy (CDDP + ETP)

p-IA

27

5

Kitai11

2014

65

F

EBUS–TBNA

Unknown (unknown)

Chemotherapy (CDDP + ETP)

c-IIIB

Unknown

6

Iwakami12

2013

56

F

VATS biopsy

Partial regression (30 days)

CRT (CDDP + ETP and RT)

c-IIIB

25

7

Mawhinney13

2010

Elderly

F

biopsy

Partial regression (7 months)

BSC

Unknown

18

8

Lee14

2008

70

F

Bronchoscopic biopsy

100% (unknown)

BSC

c-IIIA

132

9

Hirano15

2007

55

F

TBLB

Partial regression (1 month)

CRT (CDDP + ETP and RT)

c-IIIA

Unknown

10

Lowy16

1986

55

M

Node biopsy

Unknown (6 months)

BSC

Unknown

228

11

Our case

 

78

F

CT-guided PTNB

95.8% (1 month)

Surgery (lobectomy)

p-IA1

23

  1. M male, F female, EBUS–TBNA endobroncial ultrasound-guided transbronchial needle aspiration, TBLB transbronchial lung biopsy, PTNB percutaneous transthoracic needle biopsy, LD limited disease, PNS paraneoplastic syndrome, BSC best supportive care, RT radiation therapy, UIP usual interstitial pneumonia, CRT chemoradiotherapy, CDDP cisplatin, ETP etoposide, OS overall survival